Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

SAN MATEO, Calif., December 27, 2024--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd ...

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy to treat unresectable or metastatic, HER2-, PD-L1+ gastric or GEJ adenocarcinoma.

“Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...

Tevimbra plus chemotherapy reduced the risk of death by 20% compared with placebo plus chemotherapy. The Food and Drug Administration (FDA) has approved Tevimbra ® (tislelizumab-jsgr) for use in ...

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA ...